Nasdaq:STIM
Neuronetics, Inc.
Neuronetics provides non-invasive transcranial magnetic stimulation systems for treating depression and other neurological disorders.
Key Metrics
Investment Thesis
Bull Case
Investors may consider the stock if they believe the company can achieve operational leverage as revenue scales beyond $75M, potentially turning the current cash burn into profitability. The non-invasive nature of their TMS technology offers a high-growth opportunity in the expanding mental health treatment market without surgical risks. A successful expansion into new indications or international markets could validate the substantial R&D investment and improve long-term valuation.
Bear Case
The stock is risky given the deepening losses, with net profit dropping to -$43.7M while cash reserves decline rapidly to just $19.5M. High current liabilities of $31.3M against only $58.1M in current assets indicate potential liquidity pressure if financing conditions tighten. Without a clear path to positive operating cash flow, the company may face dilution through equity offerings or inability to fund future growth initiatives.
About Neuronetics, Inc.
Neuronetics develops and markets non-invasive brain stimulation systems designed to treat depression and other neurological conditions. The company serves healthcare providers and patients primarily in the United States through its proprietary TMS technology platform. Financial data reflects a focus on R&D and marketing expenditures to drive adoption of their medical devices.
Analysis
Management Discussion
Revenue grew to $74.9M in the latest period, continuing a five-year upward trend from $65.2M in 2022, yet net income deteriorated to a loss of $43.7M compared to -$30.2M the prior year. This widening loss is driven by substantial cash burn from operations (-$31.0M) and heavy investments in marketing and R&D. The company's liquidity position weakened significantly with ending cash falling to $19.5M despite debt issuances.
Industry Overview
The medical device industry for neurological treatments is competitive but growing as demand for non-surgical depression therapies increases globally. Companies in this space are navigating complex regulatory landscapes and insurance reimbursement structures which dictate market access. Consolidation is common as smaller players struggle with the high capital requirements needed for clinical trials and marketing.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $65.2M | $71.3M | $74.9M |
| Cost of Revenue | $15.5M | $19.6M | $20.7M |
| Gross Profit | $49.7M | $51.7M | $54.2M |
| Operating Expenses | $84.8M | $82.3M | $88.7M |
| Operating Income | $-35.1M | $-30.6M | $-34.6M |
| R&D | $9.3M | $9.5M | $12.8M |
| G&A | $25.5M | $25.4M | $30.3M |
| Marketing | $50.0M | $47.3M | $45.6M |
| Stock-Based Comp | $8.7M | $7.3M | $5.6M |
| D&A | $1.6M | $2.0M | $2.1M |
| Amortization | — | — | $100.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $4.3M | $5.4M | $7.3M |
| Pre-Tax Income | $-35.1M | $-30.6M | $-34.6M |
| Income Tax | $2.0M | $-365.0K | $9.2M |
| Continuing Ops | $-37.2M | $-30.2M | $-43.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-37.2M | $-30.2M | $-43.7M |
| Minority Interest | $0 | $0 | $-19.0K |
| Net to Common | $-37.2M | $-30.2M | $-43.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $98.8M | $93.8M | $58.1M |
| Cash & Equivalents | $70.3M | $59.7M | $18.5M |
| Accounts Receivable | $13.6M | $15.8M | $23.4M |
| Inventory | $8.9M | $8.1M | $4.2M |
| Prepaid Expenses | $2.2M | $4.8M | $6.8M |
| Other Current Assets | $3.8M | $5.5M | $5.2M |
| Long-Term Assets | $18.1M | $22.0M | $82.8M |
| PP&E (Net) | $2.0M | $2.0M | $6.2M |
| Intangibles | — | — | $19.6M |
| Goodwill | — | — | $18.6M |
| Operating Leases | $3.3M | $2.8M | $27.1M |
| Other LT Assets | $12.8M | $17.3M | $11.2M |
| Total Assets | $116.9M | $115.8M | $140.9M |
| Current Liabilities | $33.2M | $19.8M | $31.3M |
| Accounts Payable | $2.4M | $4.8M | $11.1M |
| Current Debt | $13.1M | — | — |
| Current Leases | $824.0K | $845.0K | $4.8M |
| Other Current Liab | $2.0M | $1.6M | $2.6M |
| Long-Term Liabilities | $26.6M | $61.8M | $77.8M |
| Long-Term Debt | $22.8M | $59.3M | $55.2M |
| LT Operating Leases | $3.0M | $2.3M | $22.7M |
| Other LT Liab | $829.0K | $200.0K | $2.0K |
| Total Liabilities | $59.8M | $81.6M | $109.1M |
| Shareholders' Equity | $57.1M | $34.2M | $31.8M |
| Retained Earnings | $-345.9M | $-376.1M | $-419.8M |
| Total L&E | $116.9M | $115.8M | $140.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-37.2M | $-30.2M | $-43.7M |
| Non-Cash Adjustments | $-5.2M | $-13.4M | $16.0M |
| Working Capital Changes | $11.6M | $11.6M | $-3.2M |
| Cash from Operations | $-30.7M | $-32.0M | $-31.0M |
| Cash from Investing | $6.7M | $-1.3M | $-2.4M |
| Debt Issuances | — | $25.0M | $57.5M |
| Debt Repayments | — | $1.2M | $60.0M |
| Cash from Financing | $207.0K | $22.7M | $-6.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-23.8M | $-10.7M | $-40.2M |
| Beginning Cash | $94.1M | $70.3M | $59.7M |
| Ending Cash | $70.3M | $59.7M | $19.5M |
Frequently Asked Questions
How does Neuronetics, Inc. make money?
The company's revenue streams are driven by sales of its TMS systems, consumables such as coils and pads required for device operation, and service agreements with healthcare providers. Financials indicate significant spending on research and development alongside marketing expenses to support market penetration. A segment related to discontinued operations shows no recent activity, suggesting a focus on continuing medical device sales.
What are the main risks for STIM?
The company faces significant cash flow challenges with a net change in cash of -$40.2M and a retained earnings deficit exceeding $419M. High operating expenses, particularly marketing at $45.6M and R&D at $12.8M, are eroding profitability despite revenue growth. Dependence on third-party manufacturers for device production creates supply chain and margin risks. Regulatory changes in healthcare reimbursement policies could impact the demand for their neurological treatment systems.
What is STIM's competitive advantage?
Neuronetics holds a strong patent portfolio protecting its non-invasive brain stimulation technology against generic competition. The company benefits from established relationships with major healthcare systems and insurance networks for reimbursement of its treatments. Its proprietary closed-loop technology differentiates it from competitors offering only open-loop magnetic stimulation solutions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.